Banerji et al.
1 described a novel MAGI3-AKT3 rearrangement in breast cancer, enriched in triple-negative tumours; the report was highly encouraging as targeted therapies could potentially serve as a new and much needed option to treat this highly aggressive breast cancer subtype. We sought to confirm the presence of this rearrangement in 236 samples of triple-negative breast cancer (TNBC) by using fluorescent in situ hybridization (FISH) and reverse transcription-polymerase chain reaction (RT-PCR), and in 84 additional cases from The Cancer Genome Atlas by using FusionSeq. No evidence of the fusion was found in any of the tumours studied. Our study confirms that MAGI3-AKT3 fusion is not a recurrent event in triple-negative breast cancer, which should be acknowledged before considering the evaluation of targeted therapies in clinical trials. There is a Reply to this Brief Communication Arising by Pugh, T. et al. Nature 520, http://dx.doi.org/10.1038/nature14266 (2015) .
TNBC constitutes the majority of breast carcinomas of the basallike molecular subtype, and is defined by absence of actionable therapeutic targets (ER, PR, HER-2). TNBC patients have a poor response to conventional breast cancer therapies 2 and experience poor survival 3 . As such, molecular elucidation of these tumours is critical in the hopes of developing novel targeted therapies 4 . Discovery of functionally recurrent gene rearrangements is a relatively new approach in breast cancer (for example, MAST kinase and Notch gene families 5 ). Banerji et al. 1 reported a MAGI3-AKT3 gene fusion to be present in 7% (5/72) of TNBC. This balanced translocation results in a constitutive activation of AKT kinase, which can be counteracted using small-molecule AKT inhibitors.
We aimed to determine the frequency of MAGI3-AKT3 fusion in 236 TNBCs represented in high-density tissue microarrays (see Table 1 ). Following previously described protocols [6] [7] [8] , FISH was performed using dual colour locus-specific probes for MAGI3 and AKT3. None of the cases showed either MAGI3 or AKT3 break-apart or fusion signals. To exclude the possibility of intra-tumour heterogeneity, multiple regions of full tumour sections were screened in a subset of 28 cases, all of which were also negative for break-apart and fusion signals (see Fig. 1 ).
Additionally, shorter primer sequences were designed to test a 187 bp fusion product of intron 9 of MAGI3 with intron 1 of AKT3 in archival material. We performed RT-PCR of cDNA in 135 of these cases. No MAGI3-AKT3 fusion product was detected. Further, we investigated RNA-seq data from 84 TNBC cases from The Cancer Genome Atlas with FusionSeq 9 . We did not find any evidence of MAGI3-AKT3 gene fusion in these cases either.
Our sample size has sufficient power to detect (with 95% confidence) gene rearrangements that would occur at a frequency of as low as 3%. Based on our results, we can reliably conclude that MAGI3-AKT3 rearrangement is neither recurrent nor sub-clonal in TNBC. To make the assumption that MAGI3-AKT3 fusion was a recurrent event in TNBC, Banerji et al.
1 interrogated their tumours by using RT-PCR of cDNA followed by Sanger sequencing only. Confirmation at the genomic level by PCR of genomic DNA was performed exclusively in the index case. Hence, we favour the view that, with the exception of the index case, the sequenced RT-PCR products by Banerji et al.
1 represent a post-transcriptional fusion event (trans-splicing), rather than a true genomic event.
Our patient cohort was mainly Caucasian women, whereas patients of Mexican and Vietnamese decent were studied in Banerji et al.
1
, raising the possibility that this rearrangement may be population-enriched, a prospect that needs further study.
Methods
Locus specific probes were located at 1p (MAGI3: BAC 59 RP11-1133G15 and 39 RP11-1008I9) and 1q (AKT3: BAC 59 RP11-931B5 and 39 RP11-989N14). At least 150 nuclei per case were interrogated in tissue microarrays. In full sections, ,2,000 nuclei per slide were evaluated. FusionSeq 9 is a robust computational tool to detect fusion transcripts in paired-end RNA-seq data [10] [11] [12] . Reads were aligned to the human reference genome sequence (GRC37/hg19) using STAR 13 . PCR primers sequences are as follows. MAGI3 forward: 59-TGTCCTTGTTCGAGCATCAC-39, MAGI3 reverse: 59-GAGGACACAGTTGCCATTGA-39, AKT3 forward: 59-TGAAAGA AGGTTGGGTTCAGA-39, AKT3 reverse: 59-GCCACTGAAAAGTTGTTGAG G-39. PGK was used as a control gene. To address this discrepancy, we analysed MAGI3-AKT3 fusions using a hybrid capture array, 'ExomePlus', that covers known exons, conserved non-coding regions and intronic regions involved in gene fusions including the ,150 kilobase first intron of AKT3. FFPE tumour and normal tissue was available from 3 positive TNBC cases from our original screen, including the index case, BR-M-045, and frozen tissue for BR-M-045. We performed ExomePlus hybrid capture and Illumina sequencing, achieving an average median read coverage of 763 (range of medians 29-144) across intron 1 of AKT3 (chr1:243, 859,018-244,006,427), on DNA from these samples.
We found 4 fusion read-pairs within intron 1 of AKT3 confirming the existence of the MAGI3-AKT3 fusion in genomic DNA obtained from frozen tissue of the index case, BR-M-045 (Fig. 1) 3 . In contrast, we failed to detect the fusion event in any tumour or normal genomic DNA obtained from FFPE tissue, including the BR-M-045 case. Screening additional DNA from 370 breast tumours, including 280 frozen tumours and 90 FFPE samples, and 372 normals (366 paired samples), also failed to find evidence of the fusion in any of these 370 tumour DNA samples at a threshold of three read pairs.
Comparison of the relative allelic fraction of the fusion event to the median allelic fraction of somatic mutations (Fig. 2) 4 , suggests that the MAGI3-AKT3 fusion event in BR-M-045 may represent a sub-clonal population of tumour cells 5 . Our initial positive observations might therefore be explained by intra-tumour heterogeneity, as well as by rare contamination with the fusion cDNA-that is, we observed the fusion in 4% of cases and in 0 controls, but we analysed only 12 negative controls. In retrospect, any such study, even by a straightforward method such as PCR, would be better powered by using a number of controls equal to the number of experimental samples.
We conclude that, although the MAGI3-AKT3 fusion occurs in at least one breast cancer case, the overall prevalence is lower than our original estimate. Indeed, the data from Mosquera and colleagues and our validation data, suggest a prevalence of ,1%. This rare alteration is oncogenically transforming and its activity is sensitive to Akt inhibition, highlighting the potential of rare genome alterations in breast cancer therapy. Furthermore, the AKT3 pathway may be important in breast cancer in light of the overexpression of AKT3 that is observed in basal-like breast cancers 6 , the expression subtype corresponding to TNBC, and it remains possible that the MAGI3-AKT3 translocation will be observed in other cancer types by genomic studies. This Reply has been written on behalf of the original author list 2 , T. J. Pugh was not a co-author of the original submitted manuscript but led the analysis of the 'ExomePlus' data. 
